EFNS guidelines for the diagnosis and management of Alzheimer's disease
Language English Country England, Great Britain Media print
Document type Journal Article, Practice Guideline
PubMed
20831773
DOI
10.1111/j.1468-1331.2010.03040.x
PII: ENE3040
Knihovny.cz E-resources
- MeSH
- Alzheimer Disease diagnosis psychology therapy MeSH
- Early Diagnosis MeSH
- Diagnostic Tests, Routine methods standards MeSH
- Diagnostic Imaging methods standards MeSH
- Diagnosis, Differential MeSH
- Humans MeSH
- Neuropharmacology methods standards MeSH
- Neuropsychological Tests standards MeSH
- Nootropic Agents therapeutic use MeSH
- Nursing, Team standards MeSH
- Caregivers standards MeSH
- Advisory Committees standards MeSH
- Physical Therapy Modalities standards MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Nootropic Agents MeSH
BACKGROUND AND OBJECTIVES: In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer's disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non-Alzheimer dementias are not included in this guideline. METHODS: The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS: The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline. CONCLUSION: A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.
References provided by Crossref.org
Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?
Dementia care in the Danube Region. A multi-national expert survey
Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
Alzheimer's disease and its treatment costs: case study in the Czech Republic
Blood markers of oxidative stress in Alzheimer's disease